BRPI1003991A2 - métodos para dosagem de uma aminopiridina, para tratamento de um distúrbio neurocognitivo ou neuropsiquiátrico, e, para preparação de um medicamento - Google Patents

métodos para dosagem de uma aminopiridina, para tratamento de um distúrbio neurocognitivo ou neuropsiquiátrico, e, para preparação de um medicamento

Info

Publication number
BRPI1003991A2
BRPI1003991A2 BRPI1003991A BRPI1003991A BRPI1003991A2 BR PI1003991 A2 BRPI1003991 A2 BR PI1003991A2 BR PI1003991 A BRPI1003991 A BR PI1003991A BR PI1003991 A BRPI1003991 A BR PI1003991A BR PI1003991 A2 BRPI1003991 A2 BR PI1003991A2
Authority
BR
Brazil
Prior art keywords
neurocognitive
aminopyridine
dosing
medicament
treating
Prior art date
Application number
BRPI1003991A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Blight
Thomas C Wessel
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of BRPI1003991A2 publication Critical patent/BRPI1003991A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1003991A 2009-08-11 2010-08-11 métodos para dosagem de uma aminopiridina, para tratamento de um distúrbio neurocognitivo ou neuropsiquiátrico, e, para preparação de um medicamento BRPI1003991A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23307709P 2009-08-11 2009-08-11
US23306909P 2009-08-11 2009-08-11
US23987709P 2009-09-04 2009-09-04
PCT/US2010/045211 WO2011019845A1 (en) 2009-08-11 2010-08-11 Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Publications (1)

Publication Number Publication Date
BRPI1003991A2 true BRPI1003991A2 (pt) 2015-09-15

Family

ID=43586462

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1003991A BRPI1003991A2 (pt) 2009-08-11 2010-08-11 métodos para dosagem de uma aminopiridina, para tratamento de um distúrbio neurocognitivo ou neuropsiquiátrico, e, para preparação de um medicamento

Country Status (17)

Country Link
US (8) US20130053420A1 (enExample)
EP (1) EP2464229B1 (enExample)
JP (2) JP6137833B2 (enExample)
KR (2) KR20120050473A (enExample)
CN (1) CN102143687B (enExample)
AR (1) AR077858A1 (enExample)
AU (1) AU2010282509B2 (enExample)
BR (1) BRPI1003991A2 (enExample)
CA (1) CA2770698C (enExample)
ES (1) ES2563751T3 (enExample)
JO (1) JO3348B1 (enExample)
MX (1) MX2012001814A (enExample)
RU (1) RU2563821C2 (enExample)
TW (2) TW201613585A (enExample)
UY (1) UY32837A (enExample)
WO (1) WO2011019845A1 (enExample)
ZA (1) ZA201201001B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2012009204A1 (en) * 2010-07-15 2012-01-19 The Trustees Of Columbia University In The City Of New York Methods for diagnosing and treating concussive disorders
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
US10905663B2 (en) 2013-03-05 2021-02-02 The University Of Chicago Treatment of demyelinating disorders
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
DE102014221687B4 (de) * 2014-10-24 2019-07-04 Danfoss Silicon Power Gmbh Leistungshalbleitermodul mit kurzschluss-ausfallmodus
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
AU2002250307A1 (en) * 2001-03-14 2002-09-24 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Improving postsynaptic response by a combination of 4-minopyridine and agonist
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
US20160213661A1 (en) 2016-07-28
CN102143687B (zh) 2015-11-25
MX2012001814A (es) 2012-06-01
WO2011019845A1 (en) 2011-02-17
UY32837A (es) 2011-03-31
US20190247379A1 (en) 2019-08-15
CN102143687A (zh) 2011-08-03
RU2012108656A (ru) 2013-09-20
HK1173911A1 (zh) 2013-05-31
ES2563751T3 (es) 2016-03-16
US20170281608A1 (en) 2017-10-05
US20170056385A1 (en) 2017-03-02
AU2010282509B2 (en) 2015-07-30
CA2770698C (en) 2018-01-30
US20130053420A1 (en) 2013-02-28
US20190015399A1 (en) 2019-01-17
KR20120050473A (ko) 2012-05-18
US20200113882A1 (en) 2020-04-16
AU2010282509A1 (en) 2012-03-01
EP2464229B1 (en) 2015-11-25
TW201110967A (en) 2011-04-01
JP2016074728A (ja) 2016-05-12
EP2464229A1 (en) 2012-06-20
ZA201201001B (en) 2014-10-29
KR20170128633A (ko) 2017-11-22
TWI549678B (zh) 2016-09-21
RU2563821C2 (ru) 2015-09-20
JP2013501805A (ja) 2013-01-17
JP6137833B2 (ja) 2017-05-31
EP2464229A4 (en) 2013-02-13
US20180147193A1 (en) 2018-05-31
TW201613585A (en) 2016-04-16
JO3348B1 (ar) 2019-03-13
CA2770698A1 (en) 2011-02-17
AR077858A1 (es) 2011-09-28

Similar Documents

Publication Publication Date Title
BRPI1003991A2 (pt) métodos para dosagem de uma aminopiridina, para tratamento de um distúrbio neurocognitivo ou neuropsiquiátrico, e, para preparação de um medicamento
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
PT2986304T (pt) Composição farmacêutica, métodos para o tratamento e suas utilizações
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015007061A2 (pt) composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
LT2729151T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
BRPI1013089A2 (pt) alimento medicinal, e, métodos para preparar um alimento medicinal, e para tratar um distúrbio metabólico
BR112014025726A2 (pt) mecanismo, sistema e método para tratamento endodôntico
EP2833971A4 (en) METHOD, SYSTEM AND USE OF THERAPEUTIC ULTRASOUND
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
BRPI1007636A2 (pt) Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
BR112013031819A2 (pt) suporte polimérico, composição farmacêutica, composto, métodos de tratar um distúrbio, e, de preparar um suporte
BR112013019637A2 (pt) sistemas, aparelho e métodos para implantação de implantes
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
BR112014031896A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um distúrbio
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
SG11201504791VA (en) Pharmaceutical composition for treating headache, and preparation method thereof
BR112014031899A8 (pt) composto, composição farmacêutica, e, método para tratamento de um distúrbio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL